miscsubjectsAI governance
Evidence review

SS-31 (Elamipretide) Mitochondrial Targeting with GLP-1 Agonists: Evidence Layers

· · 4 min read
bundle · json · system map · manifest

Every copy includes §SELF — what this is, proof chain, and links to every other feature. No context required.

§SELF — this page explains the system
## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `human_page` — **Human article page**
Rendered article with claims, sources, copy widgets, ask prompts.
- **article slug:** `ss-31-glp-1`
- **contains:** rendered article, copy widgets, claims, sources, ask prompts
- **how to use:** Use Copy for LLM or Copy system map — both paste without context.
- **read:** https://miscsubjects.com/a/ss-31-glp-1

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ss-31-glp-1/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/ss-31-glp-1/bundle?format=markdown
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/ss-31-glp-1/prompts
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/ss-31-glp-1/topology

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

*Not medical advice. Tier-honest. Cite claim/source ids.*

What's breaking down

The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.

Why SS-31 (Elamipretide) might help you

  1. Therefore for you: If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.

Why GLP-1 agonists (class) matters for you

  1. Drug: GLP-1 agonists (class)
  2. What it does: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss.
  3. Therefore for you: state whether this drug reduces load, suppresses a signal, or supports metabolism — and whether that helps or trades off repair for your condition.

How these fit together

Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.

  • SS-31 (Elamipretide) → mitochondrial

What the evidence actually shows

This is a count of what is in this ledger — not a claim about all research worldwide.

  • Scientific sources catalogued (PubMed, trials, reviews): 2
  • Claims tagged human evidence: 3
  • Claims tagged preclinical (animal/lab): 1
  • Claims tagged anecdotal: 1
  • Reddit posts catalogued: 1
  • X posts catalogued: 0
  • Other anecdote sources (YouTube, Instagram, etc.): 0
  • Total sources in chain: 4

Quantified confidence (this ledger): 0.47 / 1.00 — low–moderate — mostly preclinical

Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.

What scientists say

Mitochondrial protein interaction landscape of SS-31 (source s14)

Identifies SS-31 interactors linked to ATP production and 2-oxoglutarate metabolism.

Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.

Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy (source s5)

Class I evidence for short-term exercise improvement in PMM patients.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

What people say on Reddit

Anyone here taking other peptides along with tirzepatide? — Reddit, r/compoundedtirzepatide (source s10)

Anecdotal report of SS-31 with tirzepatide.

---

Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.

Explore this article's relationships

GLP-1 agonists · drug map

Connected articles

Where this sits in the evidence graph. Open the full interactive map for the whole neighborhood.

Full map →
RelatedSS-31 (Elamipretide) and Statin-Associated Cognitive Effects: Evidence… · 2 humanSS-31 (Elamipretide) for Carpal Tunnel Syndrome: Mitochondrial Evidenc… · 2 humanSS-31 (Elamipretide) for Chemotherapy Side Effects: Mitochondrial Evid… · 2 humanSS-31 (Elamipretide) for Chemotherapy-Induced Neuropathy: Evidence Rev… · 2 human
Evidence · 4 sources · swipe →chain a25b289ab772 · verify chain · provenance
1 / 4
Evidence ledger 6 · tier-ranked · API
human
No published human trials examine concurrent SS-31 and GLP-1 agonist use.
preclinical
SS-31 binds cardiolipin in the inner mitochondrial membrane and is associated with improved electron transport efficiency in preclinical models.
sources: s14
mechanistic
GLP-1 agonists produce weight loss that mechanically unloads the spine and joints by approximately 4 lb compressive force per pound lost.
humanlow confidence
A randomized placebo-controlled trial in primary mitochondrial myopathy patients showed dose-dependent improvement in 6-minute walk distance after 5 days of IV SS-31 (Class I evidence).
sources: s5
humanlow confidence
FDA granted accelerated approval to elamipretide (SS-31) for Barth syndrome in 2025 based on TAZPOWER trial data.
sources: s19
1 more ranked claim
anecdotal0.22low confidence
Reddit users report subjective energy or fatigue changes when using SS-31 alongside tirzepatide; reports are anecdotal and mixed.
grok/grok-4.3
Documents real-world discussion of the combination.
sources: s10
Model review1 contributions · 1 modelExpand the recursive review layer
1 / 1
grok/grok-4.3writer
redraft2026-06-29 23:55
SS-31 (Elamipretide) Mitochondrial Targeting with GLP-1 Agonists: Evidence Layers · 6 claims · 4 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: Write a data-first, evidence-graded article: Ss 31 for Glp 1
Slug: ss-31-glp-1
Audience: readers researching peptide evidence for this specific condition or drug cross.
Rules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.

ENRICHMENT BRIEF (binding section logic — one ## per compound):
{"voice":"enrichment","article_shape":"single_focus","condition":null,"condition_key":null,"primary_peptide":null,"peptides_in_scope":[{"id":"ss-31","name":"SS-31 (Elamipretide)"}],"drugs_in_scope":["glp1-agonists"],"weight_sensitive":false,"stimulant_context":false,"breaking_down":{"section_title":"What's breaking down","degenerative_why":
it output
{
  "slug": "ss-31-glp-1",
  "title": "SS-31 (Elamipretide) Mitochondrial Targeting with GLP-1 Agonists: Evidence Layers",
  "body": "## What's breaking down\n\nMitochondrial energy production can decline with age, metabolic stress, or rapid body composition changes. GLP-1 agonists drive weight loss through appetite reduction and slower gastric emptying. This often produces 1–2+ lb weekly loss, which can include lean mass if protein intake and resistance training lag. Each pound of body weight lost removes roughly 4 lb of compressive force from the spine and joints during daily movement, but the metabolic shift may also increase cellular stress on mitochondria in muscle and other tissues.\n\nSS-31 (elamipretide) is studied for its ability to bind cardiolipin in the inner mitochondrial membrane. This interaction is discussed in preclinical work as supporting electron transport chain efficiency and lowering reactive oxygen species. The article focuses on whether this mitochondrial layer interacts with the metabolic changes seen during GLP-1 use.\n\n## Why SS-31 (Elamipretide) might help you\n\nIf mitochondrial bioenergetics form part of your situation while using GLP-1 agonists, SS-31 is examined because it targets repair at the mitochondrial membrane rather than symptom masking.\n\n1. GLP-1 driven weight loss alters energy demand and substrate use.\n2. Mitochondria in muscle and
e632b8a1ef66c942
Machine verification: /api/articles/ss-31-glp-1/contributions

Related articles

GLP-1 agonists · drug map

Open evidence map →
Ss 31ss-31SS-31 (Elamipretide) for Benzodiazepine Withdrawal: Mitochondrial Repa…ss-31-benzo-withdrawalSS-31 (Elamipretide) and Benzodiazepines: Mitochondrial Pathways in a…ss-31-benzodiazepinesSS-31 (Elamipretide) and Statin-Associated Cognitive Effects: Evidence…ss-31-brain-fogSS-31 (Elamipretide) for Carpal Tunnel Syndrome: Mitochondrial Evidenc…ss-31-carpal-tunnelSS-31 (Elamipretide) for Chemotherapy Side Effects: Mitochondrial Evid…ss-31-chemo
Ask this article · 8 suggested prompts
topology · JSON · question graph

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (human tier): "No published human trials examine concurrent SS-31 and GLP-1 agonist use."?
ask ss-31-glp-1 claim c4 · paste includes §SELF
What does the ledger say about this (preclinical tier): "SS-31 binds cardiolipin in the inner mitochondrial membrane and is associated with improved electron transport efficiency in preclinical mod…"?
ask ss-31-glp-1 claim c1 · paste includes §SELF
What does the ledger say about this (mechanistic tier): "GLP-1 agonists produce weight loss that mechanically unloads the spine and joints by approximately 4 lb compressive force per pound lost."?
ask ss-31-glp-1 claim c3 · paste includes §SELF
What does the ledger say about this (human tier): "A randomized placebo-controlled trial in primary mitochondrial myopathy patients showed dose-dependent improvement in 6-minute walk distance…"?
ask ss-31-glp-1 claim c2 · paste includes §SELF
What does the ledger say about this (human tier): "FDA granted accelerated approval to elamipretide (SS-31) for Barth syndrome in 2025 based on TAZPOWER trial data."?
ask ss-31-glp-1 claim c5 · paste includes §SELF
What does the ledger say about this (anecdotal tier): "Reddit users report subjective energy or fatigue changes when using SS-31 alongside tirzepatide; reports are anecdotal and mixed."?
ask ss-31-glp-1 claim c6 · paste includes §SELF
Summarize this reddit report and how it should weigh: "Anecdotal report of SS-31 with tirzepatide."
ask ss-31-glp-1 source s10 · paste includes §SELF
For my medical situation, what can you answer from your catalogue about SS-31 (Elamipretide) Mitochondrial Targeting with GLP-1 Agonists: Evidence Layers — and what would you need me to tell you first?
ask ss-31-glp-1 condition gaps · paste includes §SELF
Add your experience or question
Think this article is wrong?
Call bullshit on CharlieOS →
Loading more articles…